🔎 Trials Near Me

Domov › Akutna mieločna levkemija › Oregon › Portland

Klinične študije za Akutna mieločna levkemija v Portland, OR

25 študij za Akutna mieločna levkemija išče udeležence na lokacijah v Portland in okolici (v razdalji približno 30 milj). Odprite študijo, da vidite, kdo lahko sodeluje in kako kontaktirati ekipo.

Uradno besedilo študije (angleško)

Iščete udeležence za študijo? Predstavite jo na vrhu te strani — $99 za 30 dni →

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Vključevanje udeležencevFaza 2
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Starost 18 in več · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT05564390

Ruxolitinib With Azacitidine Maintenance for the Treatment of Patients With Acute Myeloid Leukemia Undergoing Reduced Intensity Allogeneic Stem Cell Transplantation

Vključevanje udeležencevFaza 1
  • OHSU Knight Cancer Institute, Portland
Starost 18 in več · Vsi spoli · Posodobljeno 5. okt. 2026 · NCT07548983

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

Vključevanje udeležencevOpazovalna študijaVabljeni zdravi prostovoljci
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
  • Providence Willamette Falls Medical Center, Oregon City · 12 mi stran
Starost 40–75 · Vsi spoli · Posodobljeno 2. okt. 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

Vključevanje udeležencevFaza 2
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Starost 18–59 · Vsi spoli · Posodobljeno 28. sep. 2026 · NCT05554393

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Vključevanje udeležencevFaza 3
  • Providence Portland Medical Center, Portland
  • Providence Oncology and Hematology Care Clinic Westside, Portland
Starost 18 in več · Vsi spoli · Posodobljeno 25. sep. 2026 · NCT06852222

Ruxolitinib in Combination With Venetoclax With and Without Azacitidine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

Vključevanje udeležencevFaza 1
  • OHSU Knight Cancer Institute, Portland
Starost 18 in več · Vsi spoli · Posodobljeno 24. sep. 2026 · NCT03874052

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

Vključevanje udeležencevFaza 2
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Starost 18–59 · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT05554406

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

Vključevanje udeležencevFaza 2
  • Providence Portland Medical Center, Portland
  • Providence Saint Vincent Medical Center, Portland
Starost 18 in več · Vsi spoli · Posodobljeno 22. sep. 2026 · NCT06317649

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

Vključevanje udeležencevFaza 3
  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
6 Months – 21 Years · Vsi spoli · Posodobljeno 17. sep. 2026 · NCT04293562

Venetoclax in Combination With Cladribine and Cytarabine Alternating With Azacitidine Plus Venetoclax for the Treatment of Newly Diagnosed Monocytic AML and Active Signaling Mutated AML

Vključevanje udeležencevFaza 2
  • OHSU Knight Cancer Institute, Portland
Starost 18 in več · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT06504459

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

Vključevanje udeležencevFaza 1/2
  • Oregon Health & Science University, Portland
30 Days · Vsi spoli · Posodobljeno 16. sep. 2026 · NCT04065399

Ivosidenib and Venetoclax With or Without Azacitidine in Treating Patients With IDH1 Mutated Hematologic Malignancies

Vključevanje udeležencevFaza 1/2
  • Oregon Health and Science University, Portland
Starost 18 in več · Vsi spoli · Posodobljeno 14. sep. 2026 · NCT03471260

Revumenib in Combination With Azacitidine + Venetoclax in Patients NPM1-mutated or KMT2A-rearranged AML

Vključevanje udeležencevFaza 3
  • US-Portland OR-OHSU, Portland
Starost 18 in več · Vsi spoli · Posodobljeno 2. sep. 2026 · NCT06652438

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Vključevanje udeležencevFaza 1/2
  • Legacy Emanuel Children's Hospital, Portland
  • Oregon Health and Science University, Portland
Do 22 let · Vsi spoli · Posodobljeno 25. avg. 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

Vključevanje udeležencevFaza 3
  • Doernbecher Children's Hospital, Portland
29 Days – 21 Years · Vsi spoli · Posodobljeno 24. avg. 2026 · NCT05183035

Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT

Vključevanje udeležencevFaza 3
  • Oregon Health & Science University (OHSU) - Knight Cancer Institute, Portland
Starost 18–75 · Vsi spoli · Posodobljeno 17. jul. 2026 · NCT05429632

Pemigatinib After Chemotherapy for the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Vključevanje udeležencevFaza 1
  • OHSU Knight Cancer Institute, Portland
Starost 18 in več · Vsi spoli · Posodobljeno 14. jul. 2026 · NCT04659616

Induction and Consolidation With Fludarabine, Cytarabine, Idarubicin, and Venetoclax for the Treatment of Acute Myeloid Leukemia

Vključevanje udeležencevFaza 2
  • OHSU Knight Cancer Institute, Portland
Starost 18–65 · Vsi spoli · Posodobljeno 13. jul. 2026 · NCT07228273

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

Vključevanje udeležencevFaza 2
  • Oregon Health and Science University, Portland
Starost 18 in več · Vsi spoli · Posodobljeno 7. jul. 2026 · NCT07216443

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

Vključevanje udeležencevOpazovalna študija
  • Oregon Health & Science University/Doernbecher Children's Hospital, Portland
Vse starosti · Vsi spoli · Posodobljeno 6. jul. 2026 · NCT01351545

Iadademstat in Combination With Azacitidine and Venetoclax in Treating Newly Diagnosed Acute Myeloid Leukemia

Vključevanje udeležencevFaza 1
  • OHSU Knight Cancer Institute, Portland
Starost 18 in več · Vsi spoli · Posodobljeno 30. jun. 2026 · NCT06357182

A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)

Vključevanje udeležencevFaza 2/3
  • Oregon Health and Science University, Portland
Starost 18 in več · Vsi spoli · Posodobljeno 30. apr. 2026 · NCT04256317

A Phase 1 Study of STX-0712 in Patients With Advanced Hematological Malignancies (CMML and AML)

Vključevanje udeležencevFaza 1
  • OHSU, Portland
Starost 18 in več · Vsi spoli · Posodobljeno 9. feb. 2026 · NCT06950034

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

Vključevanje udeležencevVabljeni zdravi prostovoljci
  • Oregon Health & Science University, Portland
Starost 18–120 · Vsi spoli · Posodobljeno 25. jul. 2025 · NCT05237258

Študije za Akutna mieločna levkemija v drugih mestih

Druge študije v Portland

Vir: ClinicalTrials.gov, podatki pridobljeni 6. okt. 2026. Vsaka študija ima svoje pogoje vključitve; ekipa študije odloči, kdo lahko sodeluje.